Celgene reportedly in talks to buy Juno; Novartis’ Kymriah receives fast-track reviews in U.S. and Europe; BI’s Gilotrif gets expanded approval in lung cancer
Five things for pharma marketers to know: Friday, January 12, 2018
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
Five things for pharma marketers to know: Wednesday, December 20, 2017
Pfizer Q3 revenue driven by Prevnar sales; President Trump’s opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah